Gosset Lantibio General Information
Lantibio was a private pharmaceutical company focused on developing therapies for ocular diseases and serious respiratory conditions. Its lead programs included Moli1901/lancovutide for cystic fibrosis and Vismed® sodium hyaluronate eye drops for dry eye syndrome. The company reported positive Phase II results in cystic fibrosis with Moli1901 and advanced Vismed® into US Phase III trials under an agreement with Alcon. There are no recent updates indicating ongoing clinical development or commercialization.
Contact Information
United States
Drug Pipeline
Key Partnerships
TRB Chemedica (licensing/manufacturing partner for ophthalmology products), Alcon Laboratories Inc. (US marketing/manufacturing partner for dry eye product), AOP Orphan Pharmaceuticals AG (European licensing/commercialization partner for Moli1901/cystic fibrosis program)
Lantibio Funding
No funding data available